Corcept Therapeutics (CORT) announced after the close Friday that it received FDA approval for Korlym. The drug is a once-daily oral medicine to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.
Corcept Therapeutics gapped open sharply higher Tuesday, but traded in a narrow range throughout the session. The stock closed up by 1.42 at $4.45 on the highest volume of the year and set nearly an 8-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.